In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Consensus statement on paediatric arrhythmias released by ESC and AEPC

Extensive and practical document covers all aspects of paediatric arrhythmias

This is the first European statement concerning the diagnosis and management of paediatric arrhythmias. It is also the first joint document between EHRA and the AEPC.
Arrhythmias and Device Therapy


Sophia Antipolis, 18 July 2013: A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) and the Association for European Paediatric and Congenital Cardiology (AEPC).

“Pharmacological and non-pharmacological therapy for arrhythmias in the paediatric population” is published today in EP-Europace.1

Consensus statements have been published on arrhythmias in adults but this is the first European statement concerning the diagnosis and management of paediatric arrhythmias. It is also the first joint document between EHRA and the AEPC.

Professor Josep Brugada (Spain), Chairman of the Working Group, said: “The numbers of children with arrhythmias are relatively small and very few clinicians and centres have the necessary expertise. Paediatric arrhythmias differ from those in adults and should be treated and diagnosed in specialised centres. The ESC and AEPC decided it was necessary to outline how paediatric arrhythmias differ from adult arrhythmias and the requirements for centres that treat children.”

The paper covers four main areas: mechanisms, pharmacological treatment, radiofrequency ablation, and devices.

The first chapter explains the mechanisms of arrhythmias in children and how they differ from adults. Professor Brugada said: “Patients with congenital heart disease have specific arrhythmias during the very early years of life and after surgery which have different mechanisms to arrhythmias in adults. It’s important to understand these differences when treating children.”

Chapter two covers pharmacological treatment of paediatric arrhythmias in the acute and chronic phases. The drugs used to treat children and adults are the same, but there are different doses and indications.

Chapter three deals with radiofrequency catheter ablation, which is increasingly used in children as an alternative to antiarrhythmic drug treatment. There are important differences in children with respect to the catheters, the technique, and the indications.

Professor Brugada said: “There are some indications for ablation of arrhythmias in adults that do not apply to children because their small heart puts them at higher risk of complications. But in general, if clinicians and centres have the appropriate expertise in paediatric ablations they can be performed as safely and effectively as adult ablations, even in young children.”

The last chapter is about device treatments including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronisation therapy (CRT). Adults can keep the same device and cables for their lifetime but in children they must be replaced every 3-4 years as the child grows.

Professor Brugada said: “The document outlines how to replace the device and the cables in the heart which is a complicated procedure but can be done safely if performed in experienced centres.”

He concluded: “This extensive document covers all aspects of paediatric arrhythmias and is a working document for physicians who diagnose and treat these patients. We explain how to perform the different procedures, the indications, and how to manage complications. Centres can use it as a check list to ensure they have the equipment and experience needed to effectively treat this specialised patient population.”

References

1Pharmacological and non-pharmacological therapy for arrhythmias in the paediatric population. EHRA and AEPC-Arrhythmia Working Group joint consensus statement. EP-Europace. 2013; Europace (2013)
doi: 10.1093/europace/eut082
Full paper here:
http://europace.oxfordjournals.org/content/early/2013/07/12/europace.eut082.abstract?keytype=ref&ijkey=mFKl5HsgYSBMmT4

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death.